Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Middle East Conflict Impacts Australia and New Zealand Businesses 
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
